Prognostic factors after imatinib secondary resistance: survival analysis in patients with unresectable and metastatic gastrointestinal stromal tumors

Kanda, Tatsuo; Ishikawa, Takashi; Kosugi, Shin‐ichi; Ueki, Kazunori; Naito, Takaki; Wakai, Toshifumi; Hirota, Seiichi

doi:10.1007/s10147-015-0903-7

Cited by 4 publications

(3 citation statements)

References 23 publications

(26 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of 24 patients who underwent surgical resection of progressive diseases (PD), 20 did so as second-line treatment after imatinib therapy. Long PFS in first-line imatinib therapy, small diameter of PD and surgical resection of PD were identified as favorable independent prognostic factors (40).…”

Section: Front-line Surgery Prior To Imatinib Therapymentioning

confidence: 99%

“…In 2017, these two American institutes collected their data, analyzed clinicopathological data of 400 surgeries on 323 patients with TKI-treated metastatic GIST, and reported that surgery for metastatic imatinibtreated GIST in the absence of multifocal progressive disease was associated with outcomes at least comparable with second-line sunitinib, and may be considered in select patients (32). Kanda et al retrospectively analyzed 48 patients with unresectable and metastatic GISTs who were diagnosed with imatinib secondary resistance (ISR) and/ or underwent treatment for ISR (40). Of 24 patients who underwent surgical resection of progressive diseases (PD), 20 did so as second-line treatment after imatinib therapy.…”

Section: Front-line Surgery Prior To Imatinib Therapymentioning

confidence: 99%

See 1 more Smart Citation

Surgery for metastatic gastrointestinal stromal tumor: to whom and how to?

Kikuchi¹,

Hiramatsu²,

Kamiya³

et al. 2018

Transl. Gastroenterol. Hepatol.

View full text Add to dashboard Cite

Although imatinib is a standard treatment for metastatic or recurrent gastrointestinal stromal tumors (GISTs), acquired c-kit mutations reportedly cause secondary resistance to imatinib. Sunitinib is a tyrosine kinase inhibitor (TKI) that can be used as second-line therapy in imatinib-resistant or -intolerant GISTs. For sunitinib-resistant or -intolerant GISTs, regorafenib is a standard third-line treatment. Although TKI therapies have revolutionized the treatment of recurrent or metastatic GISTs, they cannot cure GISTs.Therefore, in the era of TKIs, role of cytoreductive surgery for recurrent or metastatic GISTs has been discussed. Retrospective studies of treatment strategies with front-line surgery prior to imatinib have shown that initial cytoreduction confers no benefit in cases of advanced or recurrent GIST, and administering imatinib is the principle treatment. Most retrospective studies report cytoreductive surgery to be feasible in patients with metastatic GIST whose disease is stable or responsive to imatinib. Cytoreductive surgery may be indicated in limited disease progression refractory to imatinib when complete resection is possible, but case selection is critical. Cytoreductive surgery for metastatic GIST treated with sunitinib seems less feasible because of high rates of incomplete resections and complications. The role of cytoreductive surgery for metastatic GISTs would be difficult to establish in a prospective study; individualized treatments need to be carefully designed based on c-kit and platelet-derived growth factor receptor alpha (PDGFRA) mutations and other factors.

show abstract

Section: Front-line Surgery Prior To Imatinib Therapymentioning

confidence: 99%

Section: Front-line Surgery Prior To Imatinib Therapymentioning

confidence: 99%

Surgery for metastatic gastrointestinal stromal tumor: to whom and how to?

Kikuchi¹,

Hiramatsu²,

Kamiya³

et al. 2018

Transl. Gastroenterol. Hepatol.

View full text Add to dashboard Cite

show abstract

“…There were 4 and 2 studies on the long-term outcomes after surgery for metastatic or recurrent GIST with partial resistance and systemic resistance to imatinib, respectively. Postoperative PFS and OS were better in the partial resistance group than in the systemic resistance group [ 93 , 126 – 128 ]. There was only one study that compared patients with and without surgery for sunitinib-resistant GIST.…”

Section: Surgical Management Partmentioning

confidence: 99%

English version of Japanese Clinical Practice Guidelines 2022 for gastrointestinal stromal tumor (GIST) issued by the Japan Society of Clinical Oncology

Hirota,

Tateishi,

Nakamoto

et al. 2024

Int J Clin Oncol

Self Cite

View full text Add to dashboard Cite

The Japan Society of Clinical Oncology Clinical Practice Guidelines 2022 for gastrointestinal stromal tumor (GIST) have been published in accordance with the Minds Manual for Guideline Development 2014 and 2017. A specialized team independent of the working group for the revision performed a systematic review. Since GIST is a rare type of tumor, clinical evidence is not sufficient to answer several clinical and background questions. Thus, in these guidelines, we considered that consensus among the experts who manage GIST, the balance between benefits and harms, patients’ wishes, medical economic perspective, etc. are important considerations in addition to the evidence. Although guidelines for the treatment of GIST have also been published by the National Comprehensive Cancer Network (NCCN) and the European Society for Medical Oncology (ESMO), there are some differences between the treatments proposed in those guidelines and the treatments in the present guidelines because of the differences in health insurance systems among countries.

show abstract

Surgery and imatinib therapy for liver oligometastasis of GIST: a study of Japanese Study Group on GIST

Kanda¹,

Masuzawa

Hirai

et al. 2017

Jpn. J. Clin. Oncol.

View full text Add to dashboard Cite

We conducted a multicenter prospective study to clarify the efficacy and safety of surgery and imatinib for liver oligometastasis of gastrointestinal stromal tumors. Eligible gastrointestinal stromal tumor patients were enrolled in the surgery trial or the imatinib trial. Primary endpoints were recurrence-free survival and progression-free survival, respectively. The trials were prematurely terminated due to amendment of guidelines for adjuvant imatinib therapy and low patient accrual. In the surgery trial, all the six patients showed hepatic recurrence: median recurrence-free survival was 145 days (range: 62-1366 days). Of the five patients receiving salvage imatinib therapy, two showed progressive disease although no death was observed. Of the five patients enrolled in the imatinib trial, one died of pneumonia after progressive disease, and four had not shown progressive disease as of last visit. The results suggest that liver oligometastasis of gastrointestinal stromal tumor may not be controllable by surgery alone and require concomitant imatinib therapy.

show abstract

Prognostic factors after imatinib secondary resistance: survival analysis in patients with unresectable and metastatic gastrointestinal stromal tumors

Abstract: Surgical resection of PD in selected cases could improve prognosis in ISR patients undergoing GIST treatment.

Cited by 4 publications

References 23 publications

Surgery for metastatic gastrointestinal stromal tumor: to whom and how to?

Surgery for metastatic gastrointestinal stromal tumor: to whom and how to?

English version of Japanese Clinical Practice Guidelines 2022 for gastrointestinal stromal tumor (GIST) issued by the Japan Society of Clinical Oncology

Surgery and imatinib therapy for liver oligometastasis of GIST: a study of Japanese Study Group on GIST

Contact Info

Product

Resources

About